title: Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.
abstract: OBJECTIVE
  We evaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST-segment elevation myocardial infarction (STEMI).
  
  
  RESULTS
  The present investigation is a prospective, single-arm, single-centre study, reporting data after the BVS implantation in STEMI patients. Quantitative coronary angiography and optical coherence tomography (OCT) data were evaluated. Clinical outcomes are reported at the 30-day follow-up. The intent-to-treat population comprises a total of 49 patients. The procedural success was 97.9%. Pre-procedure TIMI-flow was 0 in 50.0% of the patients; after the BVS implantation, a TIMI-flow III was achieved in 91.7% of patients and the post-procedure percentage diameter stenosis was 14.7 ± 8.2%. No patients had angiographically visible residual thrombus at the end of the procedure. Optical coherence tomography analysis performed in 31 patients showed that the post-procedure mean lumen area was 8.02 ± 1.92 mm(2), minimum lumen area 5.95 ± 1.61 mm(2), mean incomplete scaffold apposition area 0.118 ± 0.162 mm(2), mean intraluminal defect area 0.013 ± 0.017 mm(2), and mean percentage malapposed struts per patient 2.80 ± 3.90%. Scaffolds with >5% malapposed struts were 7. At the 30-day follow-up, target-lesion failure rate was 0%. Non-target-vessel revascularization and target-vessel myocardial infarction (MI) were reported. A non-target-vessel non-Q-wave MI occurred. No cases of cardiac death or scaffold thrombosis were observed.
  
  
  CONCLUSIONS
  In the present series, the BVS implantation in patients presenting with acute MI appeared feasible, with high rate of final TIMI-flow III and good scaffold apposition. Larger studies are currently needed to confirm these preliminary data.
authors.affiliation: Thoraxcenter, Erasmus MC, 's-Gravendijkwal 230, 3015 CE Rotterdam, the Netherlands.
authors.forename: Roberto
authors.initials: R
authors.lastname: Diletti
authors.forename: Antonios
authors.initials: A
authors.lastname: Karanasos
authors.forename: Takashi
authors.initials: T
authors.lastname: Muramatsu
authors.forename: Shimpei
authors.initials: S
authors.lastname: Nakatani
authors.forename: Nicolas M
authors.initials: NM
authors.lastname: Van Mieghem
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Onuma
authors.forename: Sjoerd T
authors.initials: ST
authors.lastname: Nauta
authors.forename: Yuki
authors.initials: Y
authors.lastname: Ishibashi
authors.forename: Mattie J
authors.initials: MJ
authors.lastname: Lenzen
authors.forename: Jurgen
authors.initials: J
authors.lastname: Ligthart
authors.forename: Carl
authors.initials: C
authors.lastname: Schultz
authors.forename: Evelyn
authors.initials: E
authors.lastname: Regar
authors.forename: Peter P
authors.initials: PP
authors.lastname: de Jaegere
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Felix
authors.initials: F
authors.lastname: Zijlstra
authors.forename: Robert Jan
authors.initials: RJ
authors.lastname: van Geuns
mesh_terms: D020341:Absorbable Implants; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*; D061665:Time-to-Treatment; D054457:Tissue Scaffolds; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000008:administration & dosage*
chemical_list: D050257:Tubulin Modulators; D000068338:Everolimus; D020123:Sirolimus
keywords: Bioresorbable vascular scaffolds; Optical coherence tomography; ST-segment elevation myocardial infarction